Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-20 Maintenance Therapy to Prevent HIV Rebound
NCT00013884Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2001
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfuvirtide in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Rebound of plasma HIV RNA. Started Mar 2001; status: completed.
02
Drugs
enfuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00013884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00013884.